Literature DB >> 20338740

Vaccines against non-communicable diseases.

Till A Röhn1, Martin F Bachmann.   

Abstract

Chronic non-communicable diseases (NCDs) are increasingly recognized as the major cause of morbidity and mortality worldwide. Effective, affordable and broadly accessible medicines for their treatment are much sought after. Therapeutic B-cell vaccines aim at inducing neutralizing auto-reactive antibodies against important mediators of such diseases. Numerous animal models have demonstrated that active immunotherapy can induce disease-modifying levels of auto-antibodies. Recent findings from clinical trials have indicated that self-reactive antibodies can also be readily induced in humans; therapeutic efficacy, however, has not always been achieved. To date, clinical experience with vaccines against self-molecules is limited. Choice of the right target, proper vaccine design, optimal vaccine dose and regimen remain the major challenges to achieve clinical efficacy and safety for this novel class of biotherapeutics. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20338740     DOI: 10.1016/j.coi.2010.02.009

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  10 in total

Review 1.  Therapeutic vaccines for chronic diseases: successes and technical challenges.

Authors:  Martin F Bachmann; Gary T Jennings
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

Review 2.  Using viruses as nanomedicines.

Authors:  H E van Kan-Davelaar; J C M van Hest; J J L M Cornelissen; M S T Koay
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

3.  Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes.

Authors:  Claudia Cavelti-Weder; Katharina Timper; Eleonora Seelig; Cornelia Keller; Martin Osranek; Ute Lässing; Gunther Spohn; Patrik Maurer; Philipp Müller; Gary T Jennings; Joerg Willers; Philippe Saudan; Marc Y Donath; Martin F Bachmann
Journal:  Mol Ther       Date:  2015-12-21       Impact factor: 11.454

4.  The Extended Impact of Human Immunodeficiency Virus/AIDS Research.

Authors:  Tara A Schwetz; Anthony S Fauci
Journal:  J Infect Dis       Date:  2019-01-01       Impact factor: 5.226

5.  Identification of matrix metalloproteinase-12 as a candidate molecule for prevention and treatment of cardiometabolic disease.

Authors:  M Amor; V Moreno Viedma; A Sarabi; N G Grün; B Itariu; L Leitner; I Steiner; M Bilban; K Kodama; A J Butte; G Staffler; M Zeyda; T M Stulnig
Journal:  Mol Med       Date:  2016-06-30       Impact factor: 6.354

6.  Peptide-based vaccination against OPN integrin binding sites does not improve cardio-metabolic disease in mice.

Authors:  Nicole G Grün; Karin Strohmeier; Veronica Moreno-Viedma; Marie Le Bras; Christine Landlinger; Karina Zeyda; Bettina Wanko; Lukas Leitner; Günther Staffler; Maximilian Zeyda; Thomas M Stulnig
Journal:  Immunol Lett       Date:  2016-09-14       Impact factor: 3.685

7.  Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells.

Authors:  Mohey Eldin El Shikh; Maciej Kmieciak; Masoud H Manjili; Andras K Szakal; Costantino Pitzalis; John G Tew
Journal:  Hum Vaccin Immunother       Date:  2013-07-08       Impact factor: 3.452

8.  Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials.

Authors:  Georgina Bowyer; Tommy Rampling; Jonathan Powlson; Richard Morter; Daniel Wright; Adrian V S Hill; Katie J Ewer
Journal:  Vaccines (Basel)       Date:  2018-07-31

9.  On the meaning of affinity limits in B-cell epitope prediction for antipeptide antibody-mediated immunity.

Authors:  Salvador Eugenio C Caoili
Journal:  Adv Bioinformatics       Date:  2012-11-14

Review 10.  Prophylactic and therapeutic vaccines for obesity.

Authors:  Ha-Na Na; Hun Kim; Jae-Hwan Nam
Journal:  Clin Exp Vaccine Res       Date:  2013-12-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.